Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood product specialist remains hopeful that Hemgenix is here to stay. “I hope ...

New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Columnist Jennifer Lynne shares her takeaways from the NOW Conference, which brought together people with VWD and other bleeding disorders.

The Border Guard Bangladesh (BGB) has written to the Border Security Force (BSF) requesting a flag meeting for the release of ...

China has approved its first gene therapy for hemophilia B, an inherited bleeding disorder caused by the deficiency of the clotting protein factor IX (FIX).

Thinking of applying for Social Security Disability Insurance? Here's how to check your eligibility and apply.

H901, has been officially approved by the National Medical Products Administration for the treatment of adult patients with moderate to severe hemophilia B.

Belief BioMed and Takeda China today jointly announced that BBM-H901, has been officially approved by the National Medical ...

This innovative injection was developed and produced by Belief BioMed, while Takeda China is responsible for its ...